Comparative Pharmacology
Head-to-head clinical analysis: ACEON versus MONOPRIL HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACEON versus MONOPRIL HCT.
ACEON vs MONOPRIL-HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACEON (perindopril) is an angiotensin-converting enzyme (ACE) inhibitor. It inhibits ACE, which converts angiotensin I to angiotensin II, a potent vasoconstrictor. This results in decreased vasopressor activity, reduced aldosterone secretion, and lower peripheral vascular resistance, leading to antihypertensive effects.
Fosinopril is an angiotensin-converting enzyme (ACE) inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion; hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing electrolyte and water excretion.
Initial: 4 mg orally once daily; titrate to 8-32 mg daily in 1-2 divided doses. Typical maintenance: 8-16 mg daily.
1 tablet (10-20 mg fosinopril / 12.5-25 mg hydrochlorothiazide) orally once daily; maximum dose 80 mg fosinopril / 50 mg hydrochlorothiazide per day.
None Documented
None Documented
Perindoprilat: terminal half-life ~30 hours (up to 120 hours in elderly or heart failure due to prolonged terminal phase from slow dissociation from ACE binding); perindopril: ~1.5 hours.
Fosinoprilat: 11.5-12 h (terminal half-life extended in renal and hepatic impairment); hydrochlorothiazide: 5.6-14.8 h (varies with renal function).
Renal: approximately 30% as perindopril and 20% as perindoprilat; fecal: approximately 50% as metabolites.
Fosinopril: renal (44%), biliary (46%); hydrochlorothiazide: renal (>95% as unchanged drug).
Category C
Category C
ACE Inhibitor
ACE Inhibitor/Diuretic Antihypertensive